TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.

I'm a paid subscriber please
log me in

I want to purchase this article for
only $1.99
(requires login)

I want to purchase five articles for
only $7.99
(requires login)

I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

Click here if you are an MIT alum and do not have access to this article.

November 2001

The Morphing Patent Problem

Absurdly broad stem cell patents are shutting down promising research.

By Seth Shulman

We've certainly learned a lot about stem cell technology recently. Late this summer, my friend George, a prominent stem cell researcher, could hardly get any work done he was so busy explaining stem cell lineages-hepatocytes, myocytes, osteoblasts-to the eager journalists and TV news crews camped in his lab.

Select from the choices above
to read the entire article.

Customer Service

Magazine Services

•	Subscription FAQ
•	Pay Your Bill
•	Renew Your Subscription
•	Change Your Address
•	Check Your Start/Expire Issue
•	Feedback
•	Buy a Back Issue
•	Permissions/Reprints
•	Cancel Your Subscription
•	Digital Subscription Customer Service